LFM-A13, BTK inhibitor (TBI1032)

Description

Product Details

Formal Name: (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide

Molecular Formula: C₁₁H₈Br₂N₂O₂

Formula Weight: 360.00

CAS Number: 62004-35-7

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 15 mg/ml).

Storage: -20°C

Stability: ≥ 2 years.

Applications

BTK inhibitor

Functions

LFM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC50’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). It has also been shown to inhibit Polo-ilke kinase (PLK) – IC50 = 61 µM for human PLK3. It displayed no activity (concentrations up to 278 µM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten tyrosine kinases.

Application Procedures

First dissolved in DMSO (up to 15 mg/ml) or in Ethanol (up to 15 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.